# A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

> **NCT00982631** · PHASE1 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Advanced/Recurrent Breast Cancer
- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Temsirolimus/PLD

## Key facts

- **NCT ID:** NCT00982631
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2012-02
- **Final completion:** 2012-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982631, "A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00982631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*